Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Eisbach Bio GmbH logo — Targeting synthetic lethality in cancer

Eisbach Bio GmbH

Targeting synthetic lethality in cancer

Founded 2019 Germany Germany 14 employees Total: $10.89M Biotechnology

General Information

Company Name Eisbach Bio GmbH
Founded Year 2019
Location Germany Germany
Employees 14
Industries Biotechnology
Business Model B2B, Platform, B2B2C
Revenue Model Product Sales, Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Eisbach Bio GmbH. To contact Eisbach Bio GmbH, visit eisbach.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Eisbach Bio GmbH compare?

A PDF of Eisbach Bio GmbH and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Eisbach Bio GmbH soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Eisbach Bio GmbH

Eisbach Bio GmbH, founded in 2019, is a promising biotechnology start-up emerging from the Biomedical Center Munich. It focuses on pioneering drugs that exploit synthetic lethality to target specific molecular vulnerabilities in cancer genomes. Their compelling slogan, "Targeting synthetic lethality in cancer," encapsulates their mission to outsmart cancer through precision medicine.

The company is headquartered in Germany and operates within the biotechnology industry. This novel approach positions Eisbach Bio as a front-runner in innovative cancer treatment, potentially addressing unmet medical needs and offering substantial market opportunities.

Recently, Eisbach Bio secured an Early VC investment on 01 June 2025 from Kalczynski Consult, signaling strong investor confidence in their cutting-edge research and commercial potential.

Business keywords: synthetic lethality, cancer therapeutics, drug development, biotechnology startup, molecular vulnerabilities, genetically defined tumors, oncology, first-in-class inhibitors, cancer genomics, screening platforms, cellular platforms

Services & Products

AI-guided molecular drug discovery
Development of next-generation small-molecule cancer therapies
Clinical trial coordination and management
Pipeline development for first-in-class allosteric therapies

Target Customers

Cancer patients Oncologists Biopharmaceutical companies Healthcare providers specializing in oncology Research institutions focusing on cancer biology

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC Undisclosed 1
Kalczynski Consult
01 Jun 2025
Early VC €4.14M 1
Cancer Focus Fund
Cancer Focus Fund
01 Mar 2024
Early VC €6.70M 1
Bavarian Ministry of Economic Affairs, Regional Development and Energy
01 Nov 2021
Support Program €50.00K 1
EIT Health
01 Aug 2019
Spinout Undisclosed 1
University Ventures
University Ventures
01 Jan 2019

Eisbach Bio GmbH Alternatives & Competitors

View All Alternatives
Eisbach Bio GmbH vs
Nodus Oncology
Nodus Oncology United Kingdom

Developing next generation DDR targeting therapies

Seed
6 employees
Biotechnology
Eisbach Bio GmbH vs
Tessellate Bio
Tessellate Bio The Netherlands

Redefining Synthetic Lethality beyond HRD

Seed
28 employees
Biotechnology
Eisbach Bio GmbH vs
Anticancer Bioscience
Anticancer Bioscience China

Applying our synthetic lethality expertise for better cancer therapies

Seed
17 employees
Biotechnology, Health Care
View all alternatives

FAQ About Eisbach Bio GmbH

Targeting synthetic lethality in cancer
Eisbach Bio GmbH was founded in 2019.
Eisbach Bio GmbH is headquartered in Germany.
Eisbach Bio GmbH operates in Biotechnology. Its work centres on synthetic lethality, cancer therapeutics, drug development and biotechnology startup. Its customers include Cancer patients, Oncologists and Biopharmaceutical companies.
Eisbach Bio GmbH has a B2B, Platform and B2B2C business model. Its revenue comes from Product Sales, Licensing and Performance Based.
Eisbach Bio GmbH has approximately 14 employees.
Eisbach Bio GmbH has completed 5 funding rounds, raising a total of $10.89M.
Eisbach Bio GmbH offers: AI-guided molecular drug discovery, Development of next-generation small-molecule cancer therapies, Clinical trial coordination and management, Pipeline development for first-in-class allosteric therapies.
Top alternatives and competitors to Eisbach Bio GmbH include Nodus Oncology, Tessellate Bio, Anticancer Bioscience, Repare Therapeutics, Breakthru Medicine. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Eisbach Bio GmbH and Nodus Oncology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Eisbach Bio GmbH, https://bouncewatch.com/company/eisbach-bio, updated 25 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes